Involving Immunoglobulin Or Antibody Fragment, (e.g., F(ab)'2, Fab', Fab, Fv, Fc, Heavy Chain, Light Chain, Etc.) Patents (Class 530/866)
  • Patent number: 6509451
    Abstract: Bis-maleimido cross-linking reagents join labelled antibodies having at least one sulphide interchain bridge. The conjugates have an enhanced binding capacity and have good blood clearance in vivo. The conjugates are of use in the diagnosis and therapy of tumors and may be prepared by reaction of the cross-linking reagent with the antibody.
    Type: Grant
    Filed: January 13, 1994
    Date of Patent: January 21, 2003
    Assignee: Celltech Limited
    Inventor: Stephen K. Rhind
  • Patent number: 6495137
    Abstract: Novel composite and humanized anti-TAG-72 monoclonal antibodies, antibody fragments, and derivatives thereof using human subgroup IV kappa light chain framework regions.
    Type: Grant
    Filed: October 30, 1997
    Date of Patent: December 17, 2002
    Assignee: The Dow Chemical Company
    Inventors: Peter S. Mezes, Ruth A. Richard, Kimberly S. Johnson, Jeffrey Schlom, Syed V. S. Kashmiri, Liming Shu, Eduardo A. Padlan
  • Patent number: 6472510
    Abstract: The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion of CD40 protein. It is based, at least in part, on the discovery that a soluble CD40/immunoglobulin fusion protein was able to inhibit helper T-cell mediated B-cell activation by binding to a novel 39 kD protein receptor on helper T-cell membranes. The present invention provides for a substantially purified CD40CR receptor; for soluble ligands of CD40CR, including antibodies as well as fusion molecules comprising at least a portion of CD40 protein; and for methods of controlling B-cell activation which may be especially useful in the treatment of allergy or autoimmune disease.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: October 29, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alejandro A. Aruffo, Jeffrey A. Ledbetter, Ivan Stamenkovic, Randolph Noelle
  • Patent number: 6468532
    Abstract: Provided are methods for treating inflammatory diseases in a patient comprising administering to the patient an effective amount of a conjugate consisting essentially of one or more antibody fragments covalently attached to one or more nonproteinaceous polymer molecules, wherein at least one antibody fragment comprises an antigen binding site that binds to human IL-8, and wherein the apparent size of the conjugate is at least about 500 kD.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: October 22, 2002
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Leonard Presta, Zahra Shahrokh, Gerardo Zapata
  • Publication number: 20020147314
    Abstract: The present invention relates to isolated and/or recombinant nucleic acids which encode primate MAdCAMs, and to proteins or polypeptides referred to herein as isolated and/or recombinant primate MAdCAMs. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a primate MAdCAM of the present invention, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant proteins; the use of nucleic acids and/or proteins in assays to identify inhibitors (e.g., antagonists) of primate MAdCAM function; and to antibodies reactive with primate MAdCAM, which are useful in in vitro methods, diagnostic and/or therapeutic applications. The invention also relates to the treatment of individuals, particularly humans, suffering from a disease (e.g.
    Type: Application
    Filed: September 8, 1997
    Publication date: October 10, 2002
    Inventors: MICHAEL J. BRISKIN, DOUGLAS J. RINGLER, DOMINIC PICARELLA, WALTER NEWMAN
  • Patent number: 6458355
    Abstract: Provided are methods for treating inflammatory diseases in a patient comprising administering to the patient an effective amount of a conjugate consisting essentially of one or more antibody fragments covalently attached to one or more nonproteinaceous polymer molecules, wherein at least one antibody fragment comprises an antigen binding site that binds to human IL-8, and wherein the apparent size of the conjugate is at least about 500 kD.
    Type: Grant
    Filed: July 24, 1998
    Date of Patent: October 1, 2002
    Assignee: Genentech, Inc.
    Inventors: Vanessa Hsei, Iphigenia Koumenis, Steven Leong, Leonard Presta, Zahra Shahrokh, Gerardo Zapata
  • Patent number: 6423546
    Abstract: The present invention relates to novel monoclonal antibodies reactive with lipid transfer proteins typically found in foaming beverages. More specifically, the present invention relates to novel monoclonal antibodies raised against the native and denatured forms of barley lipid transfer protein 1, and an assay for determining the content of said proteins in foaming beverages at various stages of their production.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: July 23, 2002
    Assignee: Miller Brewing Company
    Inventors: Lance T. Lusk, Alfonso L. Navarro, Henry Goldstein, Randall J. Wagner, David S. Ryder
  • Patent number: 6379909
    Abstract: The invention relates to a method of evaluating the immunological status of a subject comprising the steps of 1) determining the content of an antibody in a liquid sample from the subject using an immunoassay, wherein the reaction between the antibody of the sample and a ligand in the form of an antigen, an antibody or a hapten, the ligand being directed to the Fab region of the sample antibody, is carried out in the presence of other constituents of the sample to obtain a measurement 1, 2) determining the content of an antibody in the liquid sample using an immunoassay, wherein the reaction between the antibody of the sample and a ligand in the form of an antigen, an antibody or a hapten, the ligand being directed to the Fab region of the sample antibody, is carried out in the absence of other constituents of the sample to obtain a measurement 2, and 3) interrelating measurements 1 and 2 to express the interference and using the interference as a parameter for evaluating the immunological status of the subje
    Type: Grant
    Filed: June 24, 1999
    Date of Patent: April 30, 2002
    Assignee: Alk-Abello A/S
    Inventors: Hans-Henrik Ipsen, Niels Johansen, R Ikke Morkeberg, Soren Bogestrand, Tine Charlotte Beck
  • Patent number: 6376459
    Abstract: The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion of CD40 protein. It is based, at least in part, on the discovery that a soluble CD40/immunoglobulin fusion protein or antibody specific for gp39 on T cells was able to inhibit helper T-cell mediated B-cell activation by binding to a novel 39 kD protein receptor on helper T-cell membranes. The present invention provides for a substantially purified CD40CR receptor; for soluble ligands of CD40CR, including antibodies as well as fusion molecules comprising at least a portion of CD40 protein; and for methods of controlling B-cell activation which may be especially useful in the treatment of allergy or autoimmune disease, including graft-versus-host disease and rheumatoid arthritis.
    Type: Grant
    Filed: August 31, 1993
    Date of Patent: April 23, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alejandro A. Aruffo, Jeffrey A. Ledbetter, Ivan Stamenkovic, Randolph Noelle
  • Patent number: 6369195
    Abstract: Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: April 9, 2002
    Assignee: Urocor, Inc.
    Inventors: Gang An, Robert Veltri
  • Patent number: 6342219
    Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: January 29, 2002
    Assignee: Board of Regents, The University of Texas System
    Inventors: Philip E. Thorpe, Rolf A. Brekken
  • Patent number: 6333397
    Abstract: An immunoassay for the determination of myocardial necroses using antibodies to troponin T and a binding partner B for troponin T or for the an antibody, whereby either the antibody or the binding partner B is labelled with a determinable group. The immunological complex formed which contains the determinable group is isolated by separation of the phases and the determinable group is determined in one of the phases. Furthermore, monoclonal and polyclonal antibodies to troponin T are described with a cross-reactivity of less than 5% to skeletal muscle troponin T and less than 2% to troponin I and other myofibrillar proteins.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: December 25, 2001
    Assignee: Roche Diagnostics GmbH
    Inventors: Hugo Katus, Anneliese Borgya, Klaus Hallermayer, Siegfried Looser
  • Patent number: 6312690
    Abstract: Cloning of DNA fragments which code for the light chain or the heavy chain variable domain of the D7C2 monoclonal antibody within a baculovirus. The invention also concerns the expression of these DNA fragments in insect host cells, the anti-rhesus D recombinant monoclonal antibody so obtained and its use.
    Type: Grant
    Filed: July 1, 1997
    Date of Patent: November 6, 2001
    Assignees: Institut Pasteur, Proteine Performance
    Inventors: Léna Edelman, Christel Margaritte, Michel Kaczorek, Hassan Chaabihi
  • Patent number: 6299875
    Abstract: Compositions are administered to block IgE binding to receptors and ultimately displace native IgE from mast cells and related cell types, to prevent the activation of these cells during an allergic response. The compositions consist of a pharmaceutically acceptable carrier for systemic or local administration and an amount of compound binding specifically to the Fc&egr;RI IgE binding sites, and more preferably, Fc&egr;RI and Fc&egr;RII IgE binding sites, to prevent activation and degranulation of mast cells in response to exposure to allergens. The compounds can consist of IgE molecules and fragments and modifications thereof, such as IgE fragments, humanized or single chain IgE antibodies or fragments thereof, IgE with a modified Fab, non-crosslinkable IgE, or peptidomimetics which bind to the same site on the receptor as the IgE, jointly referred to herein as “IgE fragments” unless otherwise stated.
    Type: Grant
    Filed: June 4, 1998
    Date of Patent: October 9, 2001
    Assignee: Panacea Pharmaceuticals, LLC
    Inventors: Michael Caplan, Howard Sosin
  • Patent number: 6287817
    Abstract: A protein conjugate consisting of antibody directed at the pIgR and A1AT can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides us with the ability to deliver a therapeutic protein directly to the apical surface of the epithelium, by targeting the pIgR with an appropriate ligand. Thus, the highest concentration of the antiprotease will be at the apical surface, where it can do the greatest good in accelerating the inflammatory response.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: September 11, 2001
    Assignee: Case Western Reserve University
    Inventors: Pamela B. Davis, Thomas Ferkol, Elizabeth Eckman, John Schreiber, John M. Luk
  • Patent number: 6287785
    Abstract: An improved homogeneous enzyme immunoassay process for quantitatively analyzing an antigen by determining the change in the enzymatic activity caused by a reaction between the antigen and an enzyme-labeled antibody. The antigen is reacted with an enzyme-labeled antibody, followed by the reaction with a second antibody capable of recognizing and binding to a different epitope and then with a third antibody capable of recognizing and binding to the second antibody. The enzymatic activity of the labeling enzyme is determined by a water-insoluble substrate. Using the water-insoluble substrate, steric hindrance is enhanced. A highly-sensitive analysis can be carried out by a simple operation even when the antigen has a molecular weight falling within an intermediate range, for example, a range of M.W. 10,000 to 70,000.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: September 11, 2001
    Assignee: Fuji Photo Film Co., Ltd.
    Inventors: Hiroshi Shinoki, Osamu Seshimoto
  • Patent number: 6274324
    Abstract: Small specific binding molecules, such as single variable domain antibodies (Dabs) and Fv fragments, can be coupled to solid plastics surfaces or to tracers such as enzymes by means of linkers comprising polypeptides containing from 5 to 20 amino acids and which are hydrophobic and/or contain at least one lysine residue. The coupling can be achieved without significant loss of specific binding activity. The combined Dab/linker or Fv/linker can be prepared by expression in genetically-modified organisms.
    Type: Grant
    Filed: April 12, 1994
    Date of Patent: August 14, 2001
    Assignee: Unilever Patent Holdings B.V.
    Inventors: Paul James Davis, Martine Elisa Verhoeyen, Ronald Frank Jacobus De Winter
  • Patent number: 6261787
    Abstract: A bifunctional molecule consisting of a therapeutic molecule and a ligand which specifically binds a transcytotic receptor can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides the ability to deliver a therapeutic molecule directly to the apical surface of the epithelium, by targeting the transcytotic receptor with an appropriate ligand. Thus, the highest concentration of the therapeutic molecule will be at the apical surface, where it can have the greatest therapeutic effect.
    Type: Grant
    Filed: March 8, 1999
    Date of Patent: July 17, 2001
    Assignee: Case Western Reserve University
    Inventors: Pamela B. Davis, Thomas W. Ferkol, Jr., Elizabeth Eckman
  • Patent number: 6248325
    Abstract: The present invention provides a human glutathione s-transferase (HGST) and polynucleotides which identify and encode HGST. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGST and a method for producing HGST. The invention also provides for agonists, antibodies, or antagonists specifically binding HGST, and their use, in the prevention and treatment of cancer and other diseases associated with the expression of HGST. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGST for the treatment of cancer and other diseases associated with the expression of HGST. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGST.
    Type: Grant
    Filed: May 11, 1999
    Date of Patent: June 19, 2001
    Assignee: Incyte Genomics
    Inventors: Surya K. Goli, Jennifer L. Hillman
  • Patent number: 6231856
    Abstract: The subject invention concerns a method for therapeuticaly treating a patient afflicted with autoimmune disorders or disease. The subject method comprises admninistering to a patient an antibody composition that is capable of binding to and inhibiting self-reactive pathogenic anti-bodies present within the patient. Specifically exemplified is a method for treating systemic lupus erythematosis wherein the antibody composition administered to the patient comprises purified anti-DNA anti-idiotypic antibodies. The subject invention further concerns a method for purifying from pooled human gamma globulin preparations anti-idiotype antibodies useful in the present therapeutic method. The present invention further concerns a purified antibody composition useful in the present therapeutic method.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: May 15, 2001
    Assignee: University of Florida
    Inventor: Ralph Williams
  • Patent number: 6143507
    Abstract: Disclosed is a high throughput compatible assay that is useful for the identification of specific antagonists of TRAF-receptor interactions. The modular flexibility of the assay makes it possible to introduce simple modifications in order to measure the interaction of any TNF receptor cytoplasmic domain (or TRAF-binding protein) with any of the six TRAF proteins, TRAF1, TRAF2, TRAF3, TRAF4, TRAF5 and TRAF6.
    Type: Grant
    Filed: October 29, 1998
    Date of Patent: November 7, 2000
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Marilyn R. Kehry, Steven S. Pullen, James J. Crute
  • Patent number: 6132722
    Abstract: The invention is related to recombinantly produced fusion polypeptides comprising antibody V.sub.H and V.sub.L sequences operatively linked to a .beta.-lactamase for use in the delivery of cytotoxic drugs to tumor cells.
    Type: Grant
    Filed: April 30, 1998
    Date of Patent: October 17, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nathan O. Siemers, Susan Yarnold, Peter D. Senter
  • Patent number: 6129916
    Abstract: Disclosed are conjugates including a polymer backbone or microbead and binding molecules, such as Fv, Fab, or F(ab').sub.2 fragments of monoclonal antibodies or whole antibodies that are bound through their Fc carbohydrate moieties or have their Fc portion modified so that they cannot effect ADCC or complement-mediated cytolysis, and that are specific for a T cell surface antigen, such as CD3, TCR, CD4, CD8, or CD28 on T cells. The polymer or microbead is preferably made of cross-linked dextran, ficoll, latex, or agarose. The microbeads are preferably of 1 to 10 .mu.m in size, so that they can be suspended in in vivo fluids. These conjugates can be used to induce proliferation of T cells and immune stimulation, and to increase the antibody response against an administered antigen.
    Type: Grant
    Filed: November 25, 1992
    Date of Patent: October 10, 2000
    Assignee: Tanox, Inc.
    Inventor: Tse Wen Chang
  • Patent number: 6072041
    Abstract: A protein conjugate consisting of antibody directed at the pIgR and A.sub.1 AT can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides us with the ability to deliver a therapeutic protein directly to the apical surface of the epithelium, by targeting the pIgR with an appropriate ligand. Thus, the highest concentration of the antiprotease will be at the apical surface, where it can do the greatest good in accelerating the inflammatory response.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: June 6, 2000
    Assignee: Case Western Reserve University
    Inventors: Pamela B. Davis, Thomas Ferkol, Elizabeth Eckman, John Schreiber, John M. Luk
  • Patent number: 6030792
    Abstract: This invention provides novel antibodies and engineered versions thereof and methodology for monitoring biological media for protein fragments, especially collagen fragments resulting from collagenase cleavage of type II collagen.
    Type: Grant
    Filed: November 2, 1998
    Date of Patent: February 29, 2000
    Assignee: Pfizer Inc
    Inventors: Ivan G. Otterness, Peter S. Mezes, James T. Downs, Kimberly S. Johnson
  • Patent number: 5990287
    Abstract: A human monoclonal antibody specifically binding to a surface antigen of cancer cell membrane, an isolated DNA encoding the antibody, and a hybridoma producing the antibody. An anti-cancer formulation comprising the monoclonal antibody bonded to the surface of a liposome enclosing an anti-cancer agent or toxin is also provided.
    Type: Grant
    Filed: February 2, 1998
    Date of Patent: November 23, 1999
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Saiko Hosokawa, Toshiaki Tagawa, Yoko Hirakawa, Norihiko Ito, Kazuhiro Nagaike
  • Patent number: 5976877
    Abstract: Disclosed herein are monoclonal antibodies which specifically bind a protein comprising the peptide sequence represented by the sequence SEQ ID No. 1 or an immunogenic sequence of such a protein and derivatives and fragments thereof, as well as hybridomas useful for preparing them and pharmaceutical compositions in which they can be used.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: November 2, 1999
    Assignees: Institut National De La Sante Et De La Recherche Medicale (Inserm), Institut Gustave Roussy, Applied Research Systems ARS Holding N.V.
    Inventors: Thierry Hercend, Frederic Triebel
  • Patent number: 5977318
    Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 2, 1999
    Assignee: Bristol Myers Squibb Company
    Inventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady, Peter A. Kiener
  • Patent number: 5965378
    Abstract: The invention concerns a composition composed of several different antibodies or/and antibody fragments which is suitable as a reagent to reduce interferences in an immunological method for the class-specific detection of antibodies from one or several of the immunoglobulin classes G, M, A, D and E.
    Type: Grant
    Filed: April 24, 1997
    Date of Patent: October 12, 1999
    Assignee: Roche Diagnostics GmbH
    Inventors: Dittmar Schlieper, Helmut Lenz, Urban Schmitt, Volker Klemt
  • Patent number: 5965713
    Abstract: It is intended to present a sensor capable of labeling with more dyes, applying the labeled protein in immunochromatography making use of antigen-antibody reaction, and having an excellent sensitivity. In a buffer, a protein and a first covalent bonding compound that can react with this protein are reacted to prepare a protein conjugate, then a cyanine labeling dye is added in the buffer containing the protein conjugate, and the protein conjugate and cyanine labeling dye are reacted to prepare a dye labeled protein conjugate. Alternatively, in a buffer solution, a protein and a cyanine labeling dye are reacted to prepare a dye labeled protein, then a first covalent bonding compound that can react with the protein is added in the buffer containing the dye labeled protein, and the dye labeled protein and first covalent bonding protein are reacted to prepare a dye labeled protein conjugate.
    Type: Grant
    Filed: November 8, 1996
    Date of Patent: October 12, 1999
    Assignee: Matsushita Electric Industrial Co., Ltd.
    Inventors: Nobuyuki Shigeto, Jinsei Miyazaki, Hiroshi Nakayama
  • Patent number: 5959083
    Abstract: The invention relates to bispecific tetravalent receptors of the formula I ##STR1## or formula II ##STR2## against a tumor-associated antigen and against an agent active against tumors.
    Type: Grant
    Filed: September 21, 1994
    Date of Patent: September 28, 1999
    Assignee: Behringwerke Aktiengellschaft
    Inventors: Klaus Bosslet, Gerhard Seemann
  • Patent number: 5895811
    Abstract: The invention relates to an artificial positive control reagents based on antibody conjugates that are used in immunochemical detection methods and to processes for the preparation of these reagents.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 20, 1999
    Assignee: Behring Diagnostics GmbH
    Inventors: Stefan Brust, Heinz-Juergen Friesen, Guenther Nau, Hans-Erwin Pauly
  • Patent number: 5885579
    Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
    Type: Grant
    Filed: July 8, 1997
    Date of Patent: March 23, 1999
    Assignee: Briston-Myers Squibb Company
    Inventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady, Peter A. Kiener
  • Patent number: 5849583
    Abstract: The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with non-HIV-1 antibodies. The present invention provides methods of diagnosis, monitoring and treatment of HIV-related diseases through the use of this antibody or related compounds.
    Type: Grant
    Filed: August 20, 1993
    Date of Patent: December 15, 1998
    Assignee: Sidney Kimmel Cancer Center
    Inventors: Sybille Muller, Haitao Wang
  • Patent number: 5846735
    Abstract: The present invention involves the detection and purification of Hepatitis C Virus (HCV). More particularly, the invention involves the exploitation of a newly discovered Fc-binding function in HCV to capture HCV from infected samples. This permits greatly simplified methods of diagnosis, improved methods of treatment and, in addition, the first opportunity to purify significant quantities of HCV.
    Type: Grant
    Filed: April 18, 1996
    Date of Patent: December 8, 1998
    Assignee: University of Iowa Research Foundation
    Inventors: Jack T. Stapleton, Jian-Qiu Han, Douglas LaBrecque, Warren N. Schmidt
  • Patent number: 5837821
    Abstract: An antigen binding protein construct or "minibody" which includes the VL and VH domains of a native antibody fused to the hinge region and CH3 domain of the immunoglobulin molecule is described. Minibodies are small versions of whole antibodies which encode in a single chain the essential elements of a whole antibody. Minibodies are expressed by host cells transformed with minibody genes.
    Type: Grant
    Filed: June 24, 1994
    Date of Patent: November 17, 1998
    Assignee: City of Hope
    Inventor: Anna M. Wu
  • Patent number: 5834187
    Abstract: The invention relates to the isolation and cloning of the structural gene, hipP, for the NTHi pili serotype 5 and the LKP operon. The invention relates to DNA molecules capable of hybridizing to the DNA sequences of the Haemophilus influenzae genome related to the pili. The invention further relates to a DNA molecule which encodes a pili protein, particularly a tip adhesion protein. The DNA molecules of the invention can be used in a method for assaying a sample, such as a blood sample, for the presence of Haemophilus influenzae in the sample. Accordingly, the invention further relates to the use of the DNA molecules as a diagnostic. The invention also relates to a recombinant Haemophilus influenzae pili protein, such as a tip adhesion protein. The protein can be employed in a method for immunizing an animal, such as a human, as a therapeutic or diagnostic.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 10, 1998
    Assignee: Bactex, Inc.
    Inventors: Bruce A. Green, Charles C. Brinton, Jr.
  • Patent number: 5795967
    Abstract: Tumor necrosis factor antagonists are administered in therapeutically effective doses to suppress inflammatory immune-potentiated events. The antagonists of this invention typically are selected from among several classes but preferably are neutralizing antibodies directed against tumor necrosis factor. The antagonists are useful in suppressing transplantation immunity and in the treatment of autoimmune diseases.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 18, 1998
    Assignee: Genentech, Inc.
    Inventors: Bharat B. Aggarwal, Michael A. Palladino, Mohamed R. Shalaby
  • Patent number: 5767246
    Abstract: A human monoclonal antibody specifically binding to a surface antigen of cancer cell membrane, an isolated DNA encoding the antibody, and a hybridoma producing the antibody. An anti-cancer formulation comprising the monoclonal antibody bonded to the surface of a liposome enclosing an anti-cancer agent or toxin is also provided.
    Type: Grant
    Filed: December 20, 1994
    Date of Patent: June 16, 1998
    Assignee: Mitsubishi Chemical Corporation
    Inventors: Saiko Hosokawa, Toshiaki Tagawa, Yoko Hirakawa, Norihiko Ito, Kazuhiro Nagaike
  • Patent number: 5759546
    Abstract: A method for the selective depletion of activated CD4.sup.+ T-cells in vivo by using immunotoxins comprising the OX-40 antibody conjugated to a toxic molecule (such as Ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4.sup.+ T-cells which have been implicated in diseases including Multiple Sclerosis, Rheumatoid Arthritis, Sarcoidosis, and Autoimmune Uveitis. This type of therapy is also beneficial for eradicating CD4.sup.+ T-cell lymphomas and alloreactive CD4.sup.+ T-cells involved with a transplantation reaction. The use of the human form of the OX-40 antibody will also help in the early diagnosis of all the diseases mentioned above.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: June 2, 1998
    Inventors: Andrew D. Weinberg, Arthur A. Vandenbark
  • Patent number: 5747654
    Abstract: The present invention relates to disulfide-stabilized recombinant polypeptide molecules which have the binding ability and specificity for another peptide, such as the variable region of an antibody molecule. Methods of producing these molecules and nucleic acid sequences encoding these molecules are also described. In particular, the invention discloses Fv antibody fragments stabilized by a disulfide bond connecting the V.sub.H and V.sub.L regions of the Fv fragment. The .alpha. and .beta. chains of T cell receptors may be similarly stabilized by means described in the invention.
    Type: Grant
    Filed: June 14, 1993
    Date of Patent: May 5, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ira H. Pastan, Byungkook Lee, Sun-Hee Jung, Ulrich Brinkmann
  • Patent number: 5736138
    Abstract: A monoclonal antibody, or fragments thereof, against human TNF receptor protein which antibody neutralizes the known actions of TNF.alpha. and/or TNF.beta. is disclosed. The antibody may be chimeric or humanized. Furthermore, the present invention provides a process for obtaining the above monoclonal antibody, as well as a pharmaceutical composition containing the above monoclonal antibody and/or the above protein with antibody properties.
    Type: Grant
    Filed: February 12, 1991
    Date of Patent: April 7, 1998
    Assignees: Klaus Pfizenmaier, Peter Scheurich, Bettina Thoma
    Inventors: Klaus Pfizenmaier, Peter Scheurich, Bettina Thoma
  • Patent number: 5709859
    Abstract: Mixed specificity fusion proteins capable of binding to cellular adhesion molecules have been produced. The fusion proteins contain a polypeptide region, such as an IgG constant region, operatively attached to at least two binding regions each of which corresponds to either an extracellular domain of a cell surface receptor for cellular adhesion molecules, or a variable region of an antibody directed to a cellular adhesion molecule.A method of inhibiting inflammation is a patient is disclosed in which the present fusion proteins are administered to a patient to inhibit the attachment of inflammatory cells to vascular endothelium.A method of inhibiting metastasis is disclosed in which the present fusion proteins are administered to a patient to inhibit the metastasis of responsive tumor cells.
    Type: Grant
    Filed: January 24, 1991
    Date of Patent: January 20, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alejandro A. Aruffo, Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, H. Perry Fell, Jr.
  • Patent number: 5690935
    Abstract: Cytotoxic biotherapeutic agents effective for treating certain types of cancer in humans are provided which comprise the TP-3 murine monoclonal antibody chemically conjugated to pokeweed antiviral protein (PAP). The invention further provides a method which utilizes the disclosed cytotoxic biotherapeutic agents to systemically treat cancer patients. With slight modifications the method of the present invention should be generally applicable to preparation and use of other cytotoxic biotherapeutic agents using chemical or recombinant derivatives of the TP-3 or TP-1 antibodies or PAP toxin. The invention is applicable to cancer patients who express the p80 antigen recognized by the TP-1/TP-3 antibodies either on the surface of their tumor cells or on the tumor blood vessels.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: November 25, 1997
    Assignee: Regents of the University of Minnesota
    Inventors: Fatih M. Uckun, Peter M. Anderson
  • Patent number: 5688766
    Abstract: The present invention relates to oral and edible compositions intended to provide an anticaries benefit. The primary active ingredient in these compositions is a protein selected from the group consisting of cystatin S, cystatin SA, cystatin SN and mixtures thereof which are salivary proteins. Also included are fragments of the proteins which may be used in place of the total proteins.
    Type: Grant
    Filed: August 23, 1995
    Date of Patent: November 18, 1997
    Inventor: George Joe Revis
  • Patent number: 5681930
    Abstract: The present invention relates to monoclonal antibodies that define Oncostatin M, a novel cytokine. The monoclonal antibodies of the invention are capable of binding to Oncostatin M, inhibiting Oncostatin M receptor binding, and/or inhibiting Oncostatin M bioactivity. Such antibodies may be used to detect the presence at Oncostatin M and/or to modulate Oncostatin M bioactivities in an in vivo or in vitro system.
    Type: Grant
    Filed: September 10, 1992
    Date of Patent: October 28, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: Susan F. Radka, Peter S. Linsley, Mohammed Shoyab
  • Patent number: 5677425
    Abstract: The present invention provides an altered antibody molecule (AAM) having a hinge region which has a different number of cysteine residues from that found in the hinge region normally associated with the CH1 domain of the antibody molecule and a process for producing the same using recombinant DNA technology.
    Type: Grant
    Filed: August 18, 1994
    Date of Patent: October 14, 1997
    Assignee: Celltech Therapeutics Limited
    Inventors: Mark William Bodmer, John Robert Adair, Nigel Richard Whittle
  • Patent number: 5677280
    Abstract: Described are peptides and peptide mimetics that bind to and the IL-5 receptor. Such peptides and peptide mimetics are useful in methods for treating disorders that involve improper production of or response to IL-5 and or the production and accumulation of eosinophils, such as asthma, as well as in diagnostic methods employing labeled peptides and peptide mimetics.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 14, 1997
    Assignee: Glaxo Group Limited
    Inventors: Ronald W. Barrett, Bruce P. England, Peter J. Schatz, Derek Sloan, Min-Jia Chen
  • Patent number: 5672688
    Abstract: A composition comprising as an active ingredient a compound consisting of an immunoglobulin F.sub.c fragment and an alkylating, antibiotic, or antimetabolic antitumor substance bound thereto, and a pharmaceutically acceptable carrier is disclosed. The Fc fragment moiety in the compound is stable in a living body, and thus the activity of the antitumor substance therein is maintained over a long period.
    Type: Grant
    Filed: July 20, 1993
    Date of Patent: September 30, 1997
    Assignee: Kureha Chemical Industry Co., Ltd.
    Inventors: Akira Kobayashi, Takao Ando, Masahiko Fujii
  • Patent number: 5639863
    Abstract: The variable chains of two human monoclonal antibodies (HMAbs) of the IgM isotype are characterized by elucidation of cDNAs encoding those chains. The HMAbs are specific against cell cycle independent, glioma-associated antigen, and the antibodies do not recognize cultured normal human astrocytes. Immunoconjugates based on the sequences identified should target both proliferating and non-proliferating glioma cells in vivo, thus providing a valuable adjunctive therapy in the treatment of these tumors.
    Type: Grant
    Filed: June 21, 1994
    Date of Patent: June 17, 1997
    Inventor: Michael D. Dan